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Objective. The eﬃcacy of inﬂuenza vaccination in patients treated with Japanese Oriental (Kampo) Medicine is unknown. The
objectives of this study were to observe the eﬃcacy of inﬂuenza vaccination in RA patients treated with Kampo. Methods.T r i v a l e n t
inﬂuenza subunit vaccine was administered to 45 RA patients who had received Kampo. They were divided into 2 groups: RA
patientstreatedwithoutMTX(“withoutMTXgroup”)andtreatedwithMTX(“withMTXgroup”).Antibodytitersweremeasured
before and 4 weeks after vaccination using hemagglutination inhibition assay. Results. Geometric mean titers (GMTs) of anti-
inﬂuenza antibodies signiﬁcantly increased for all inﬂuenza strains. Response to the inﬂuenza vaccination in RA patients treated
with Kampo was not lower than that of healthy subjects and the response in the “with MTX group” had a tendency to be higher
than that in RA patients treated with MTX in the previous study. There was no signiﬁcant diﬀerence in the GMT after 4 weeks
between the “with MTX group” and the “without MTX group.” A decreased eﬃcacy in both seroprotection and seroconversion
was not found in the “with MTX group.” Conclusion. These observations may open the way for further clinical trials to establish
the eﬃcacy for the inﬂuenza vaccination in RA patients treated with Kampo.
1.Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
that is associated with immunologic changes in T cells and
B cells. In patients with RA, an impaired ability to react to
antigens and an increased peripheral blood CD4/CD8 ratio
h a sb e e no b s e r v e di nTc e l l s[ 1, 2]. The presence of soluble
interleukin-2 (IL-2) receptors in serum has showed T cell
activation[2,3].Furthermore,Tcellreceptorrearrangement
excision circles measured from T cells from RA patients were
substantially lower than those in healthy controls, because
theTcellreceptorrepertoirehasbeenoligoclonal,whichsug-
gests on antigen selection and restriction of the repertoire
[4]. There is also a decline in the thymic output of T
cells. This premature aging of T cells in RA may have very
severe eﬀects on vaccine responses, which are well known to
decrease with aging [5]. Additionally, the function of regula-
tory T cells (CD4+, CD25+) may be abnormal in active RA
patients, with a lack of suppression of CD4+ or CD8+ T cells
[6].
The multiple immunologic eﬀects of the disease process
may in part explain why patients with RA are considered im-
munocompromised and at increased risk of infection [7].
Therefore, although the exact prevalence, morbidity, and
mortality of inﬂuenza in patients with RA are unknown, a
yearly inﬂuenza vaccination is recommended [8]. The inﬂu-
enzavaccinationissafeandresultsinprotectivelevelsofanti-
inﬂuenza antibodies in most RA patients, even when they are
treated with prednisone, disease-modifying antirheumatic
drugs (DMARDs), or tumor necrosis factor-blocking agents
[9, 10].
In Japan, Japanese traditional herbal (Kampo) Medicine,
which is covered by national health insurance, is often2 Evidence-Based Complementary and Alternative Medicine
prescribed in the primary care ﬁeld and is also applied as an
alternative treatment for serious diseases such as RA. Since
ancient times, many kinds of Kampo formulae have been
used traditionally and are found to be clinically eﬀective for
RA treatment. These formulae usually contain components
from several medicinal plants that are thought to exert
anti-inﬂammation and immune-regulator eﬀects and are
eﬀective for treating RA [11–13]. We have demonstrated
that kampo formula possessed antirheumatic eﬀects in vitro
and in vivo [14, 15]. Furthermore, we have observed that
the administration of kampo formula partially suppressed T
cell activation in collagen induced arthritis (CIA) mice [16].
However, the eﬀectiveness of the inﬂuenza vaccination in
RA patients treated with Kampo remedy is still not known.
The purpose of this study is to investigate the response to
the inﬂuenza vaccination in RA patients treated with Kampo
remedy.
2. Patientsand Methods
2.1. Patient’s Proﬁle. Patients who visited our department in
2010-2011 had to fulﬁll the American College of Rheuma-
tology 1987 revised criteria for the classiﬁcation of RA and
wereselectedin arandom sampling method. Allpatients had
been treated with Kampo formulae, which were often admi-
nistered to the patients with RA.
2.2.StudyDesign. Anobservationalstudydesignwasutilized
inthisstudy.Forty-ﬁvepatientswereenteredintothisdesign.
Patients received the inﬂuenza vaccine intramuscularly from
October 2010 until January 2011. Immediately before and 4
weeks after vaccination, blood was drawn for the measure-
ment of C-reactive protein levels (CRP), erythrocyte sed-
imentation rate (ESR), and anti-inﬂuenza antibodies. The
DiseaseActivityScorein28joints(DAS28)[17]wasrecorded
before and 4 weeks after vaccination. Information on pre-
vious inﬂuenza vaccinations was obtained from all partici-
pants, and adverse eﬀects occurring in the ﬁrst 7 days post-
vaccination were recorded. This study was approved by the
Ethics Committee of Gunma Central & General Hospital in
Aug 2010.
2.3. Vaccine. We used a trivalent inﬂuenza subunit vaccine
(2010-2011; Daiichi-Sankyo co.ltd Tokyo Japan) containing
puriﬁed hemagglutinin and neuramidase of the following
strains: A/California/7/2009 (H1N1)-like strain (A/H1N1
strain), A/Victoria/210/2009 (H3N2)-like strain (A/H3N2
strain), and B/Brisbane/60/2008-like strain (B strain).
2.4. Hemagglutination Inhibition Assay (HIA). The HIA was
used for the detection of anti-inﬂuenza antibodies. HIAs
were performed with guinea pig erythrocytes in accordance
with standard procedures [18]. The following parameters for
eﬃcacy of the vaccination based on the anti-inﬂuenza anti-
body response were evaluated: geometric mean titer (GMT),
fold increase in titer, 4-fold titer rise resulting in a postvac-
cination level of 40 (seroconversion), and titer rise to 40 ≥
(seroprotection). HIA titers 40 are generally considered to be
protective in healthy adults [19].
3. Results
3.1. Patient Characteristics. Forty-ﬁve RA patients were ad-
ministered Kampo treatment. They were divided into 2
groups as follows: 16 RA patients treated without MTX
(without MTX group) and 23 RA patients treated with MTX
(with MTX group). Patients treated with tacrolimus (TAC)
or biologics were excluded from the patients in the without
MTX group, and patients treated with biologics were exclud-
edfromthepatientsinboththewithMTXandwithoutMTX
group. Their characteristics were shown in Table 1.
3.2. The Response to the Inﬂuenza Vaccination. Each GMT
after 4 weeks vaccination was 78.8 ±119.7, 35.7 ±33.6, and
27.3 ± 27.3 in A/H1N1, A/H3N2, and B strain, respectively
(Table 2). Response to the inﬂuenza vaccination in RA pa-
tients treated with Kampo formulae was not lower than that
of healthy subjects in previous studies [20, 21]. There was no
signiﬁcant diﬀerence in the GMT after 4 weeks between the
“withMTXgroup”andthe“withoutMTXgroup.”TheGMT
in the with MTX group was higher than in the without MTX
group (Table 2). The response in the with MTX group had a
tendency to be higher than that in RA patients treated with
MTX in the previous study [21]. Furthermore, we calculated
the fold increase as well as the GMT. The mean fold increase
in each group was as follows: 6.5, 2.6, and 2.1, respectively
(Table 2). The fold increase in the with MTX group also had
a tendency to be higher than in the without MTX group,
although this was not signiﬁcant.
3.3. Seroprotection and Seroconversion. After 4 weeks vacci-
nation, the percentage of patients who possessed the 40 ≥
titer in A/H1N1 was 53.3, 50.0, and 65.2% in total RA pa-
tients, without MTX group and with MTX group, respec-
tively (Figure 1). There was no signiﬁcant diﬀerence between
the with MTX and the without MTX groups and a decreased
eﬃcacy in seroprotection was not found in the with MTX
group. In A/H3N2, the percentage of patients who possessed
the 40 ≥ titer was 46.7, 50.0, and 52.2%, and in the B strain,
28.9, 25.0, and 39.1% in total RA patients, without MTX
group, and with MTX group, respectively. The seroprotec-
tion eﬀect observed in the with MTX group had a tendency
to be higher than results in the previous study [21]. In
seroconversion, the percentage of patients who possessed 40
≥ titer induced by 4-fold increase was 40.0, 35.6, and 15.6%,
respectively (A/H1N1, A/H3N2, and B Strain). There was no
signiﬁcantdiﬀerencebetweenthewithMTXandthewithout
MTX groups also in seroconversion (data not shown).
3.4. The Inﬂuence of Inﬂuenza Vaccination upon RA Disease
Activity. The DAS28 did not change after vaccination. There
was no adverse reaction by inﬂuenza vaccination.
4. Discussion
Kampo medicine, which is covered by national health insur-
ance in Japan, is often prescribed in the primary care ﬁeld,Evidence-Based Complementary and Alternative Medicine 3
Table 1: Characteristics at baseline of RA patients in this study.
Total Without MTX group∗ With MTX group∗∗
Age, mean± SD years 56.2 ± 13.55 8 .6 ± 10.55 4 .1 ± 12.6
No.(%)female/No.(%)male 42(93)/3(7) 15(94)/1(6) 22(92)/2(8)
Duration of RA mean±SD years 12.2 ± 14.11 3 .5 ± 15.61 0 .9 ± 11.6
MTX dosage,mean ±mg/week 5.1 ± 3.80 7 .6 ± 2.5
PSL dosage, mean ±SD mg/day 2.1 ± 2.01 .6 ± 1.52 .4 ± 1.9
Taking DMARDs, No.
Bucillamine 1 1 0
Sulfasalazine 11 8 2
Tacllolimus 4 0 4
DAS28 CRP 3.2 ± 1.12 .9 ±1.03 .3 ±1.4
∗Without MTX group: patients treated with classical DMARDs alone. Patients treated with tacllolimus were excluded. ∗∗with MTX group: patients treated
with MTX, but not biologics.
Table 2: GMTs and fold increase in GMT for inﬂuenza A/H3N2, A/H1N1, and B strains in RA patients treated with Kampo formulae before
and after administration of inﬂuenza vaccines.
Total Without MTX group∗ With MTX
group∗∗
GMT, mean ±SD
A/H1N1 strain
Baseline 12.1 ±14.01 1 .0 ± 12.11 4 .1 ± 15.0
4w e e k sl a t e r 7 8 .8 ±119.73 9 .6 ± 39.3 115.9 ± 148.8
A/H3N2 strain
Baseline 13.5 ±13.91 6 .0 ±19.71 1 .7 ±10.2
4w e e k sl a t e r 3 5 .7 ±33.63 3 .1 ± 21.83 9 .1 ± 40.2
Bs t r a i n
Baseline 12.8 ±10.31 3 .9 ±9.21 1 .4 ±11.5
4w e e k sl a t e r 2 7 .3 ±27.82 2 .8 ±19.23 1 .4 ±34.0
Fold increase, mean (range)
A/H1N1 strain 6.5(1 to 64) 3.6(1 to 16) 8.2(1 to 64)
A/H3N2 strain 2.6(1 to 16) 2.1(1 to 8) 3.3(1 to 16)
B strain 2.1(1 to 16) 1.6(1 to 4) 2.7(1 to 16)
∗Without MTX group: patients treated with classical DMARDs alone. Patients treated with tacllolimus were excluded. ∗∗with MTX group: patients treated
with MTX, but not biologics.
and is also applied as an alternative remedy for RA. The eﬃ-
cacy for RA of Kampo medicines has been demonstrated by
case or case series reports and several clinical trials. From
these reports, the clinical eﬀectiveness of Kampo therapy is
almost similar to that of classical DMARDs, such as bucil-
lamine (Bc) and salazosulfapyridine (SASP). Additionally,
several investigators have demonstrated the immunomodu-
latory eﬀects of Kampo medicine in RA patients as well as an
arthritismousemodel,suchasCIA[11,12,14].Wehavealso
reported that Kampo therapy resulted in a decrease in serum
IL-6levels,butnotTNF-αlevels,aswellasthesuppressionof
arthritis development, based on the observations of the CIA
mouse model [15]. Furthermore, it has been reported that
Kampo medicine is probably eﬀective against infection. The
eﬃcacy of Kampo therapy on atypical mycobacterium pneu-
monia and aspiration bacterial pneumonia has been demon-
strated [22, 23], and these eﬀects may be caused by immu-
ne-regulator eﬀects, but not direct antibacterial eﬀects. On
the other hand, RA patients are susceptible to both viral and
bacterial infections. In Japanese RA patients, major causes
of death included malignancies (24.2%), respiratory involve-
ment (24.2%) including pneumonia (12.1%) and interstitial
lung disease (ILD) (11.1%), cerebrovascular disease (8.0%),
and myocardial infarction (7.6%) [24]. Infectious disease is
one of the critical factors in the mortality of RA patients.
Therefore, a yearly inﬂuenza vaccination is recommended by
the Center for Disease Control and Prevention (CDC) [25,
26].However,theimmuneresponsetotheinﬂuenzavaccina-
tion has not been reported in RA patients treated with Kam-
pomedicine.Thisistheﬁrstreportdemonstratingthetiterof
anti-inﬂuenza antibodies before and after inﬂuenza vaccina-
tion in RA patients administered Kampo formulae.
The response to the inﬂuenza vaccination in our popula-
tion was almost similar to previous results in healthy sub-
jects. Kampo therapy may be beneﬁcial for RA patients
from the clinical viewpoint of protection against inﬂuenza4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Percentage of patients with anti-inﬂuenza titers ≥40, as
determined by a hemagglutination inhibition assay for each strain
after vaccination with a trivalent inﬂuenza subunit vaccine, in total
RApatients, RA patients treated with MTX,and RA patients treated
without MTX. Solid bars represent prevaccination titer ≥40; open
bars represent post vaccination titer ≥40.
virus infection as well as suppression of RA disease activity.
However, there are various opinions about the eﬃcacy of the
inﬂuenza vaccination in RA patients. Some reports demon-
strate both no diﬀerences and signiﬁcant diﬀerences in the
response rate between treatment with and without MTX in
RA patients [20, 27–29]. This discrepancy may be caused
by the diﬀerent endpoints when measuring the response to
the inﬂuenza vaccination and diﬀerent inﬂuenza virus roots.
Therefore, our data should be limited in reference to the
adjuvant eﬀects of Kampo therapy. However, as the baseline
titers in this study were less than previous studies, we consi-
der Kampo therapy to be partially beneﬁcial for RA patients
in seroprotection and seroconversion. In addition, it has
been reported that the response to vaccination was signif-
icantly less in patients treated with anti-TNF-a and anti-
CD20 antibody (rituximab) drugs than RA patients without
biologics[21,29].Wehavecheckedthetitersofthe5patients
treated with biologics, and they were less than those of other
RA patient groups (data not shown). Kampo therapy may
not inﬂuence the response to the inﬂuenza vaccination in
RA patients treated with biologics. To analyze this problem,
further clinical observational studies will be required using a
large number of patients.
The RA disease activity by DAS28 did not change after
vaccination in our patients. It is generally thought that the
vaccination does not inﬂuence the disease activity and the
titer of the serological markers. A recent report demonstrates
that inﬂuenza vaccination did not alter the percentage of
healthy adults with positive autoantibodies [30].
WehavereportedseveralpatientswithMTX-resistantRA
as being successfully treated with Kampo medicine; however,
it is still not clear as to how Kampo medicine acts on arthritis
in humans [31]. We previously demonstrated that Kam-
po medicine suppressed polyclonal B cell activation, but not
T cell activation, signiﬁcantly in the CIA mouse model [14,
15]. Recently, it has been clariﬁed that the development of
arthritis in the CIA mouse contributed to the diﬀerentiation
of IL-17 producing cells (Th17), dependent on IL-6 and
TGF-β [32, 33]. In our previous study using CIA, Kampo
medicine decreased the serum IL-6 levels, but not TNF-α,
suggesting that the suppression of Th17 cell activation by
Kampo therapy probably improved the development of art-
hritis. Thus, we suggest that Kampo medicines do not inﬂue-
nce the function of antigen presentation in dendrite cells or
macrophages. Based on these ﬁndings, we suggest that Ka-
mpo therapies do not suppress the response to the inﬂuenza
vaccination in RA patients. Besides, in innate immunity, we
have demonstrated that Juzentaihoto enhanced the produc-
tion of iNOS in macrophages [34] and the upregulation of
NK receptor’s expression (Killer-cell immunoglobulin-like
receptors) in NK cells [35]. Additionally, the direct anti-in-
ﬂuenzavirusactionsofcinnamoncortexandephedraeherba
(the main herbs composing kampo formulae) have been
demonstrated,whiletheseactionsarenotassociatedwiththe
response to vaccination in RA patients treated with Kampo
[36, 37].
In conclusion, we have demonstrated the changes in the
titer of each anti-inﬂuenza antibody before and after vacci-
nation in RA patients treated with Kampo formula. A low
response to the vaccination was not observed compared with
previous studies, and in the MTX-treated patients group, the
response to vaccination was higher in our study than in pre-
viousreports.Thepresentobservationsmayopenthewayfor
furtherclinical trialsto establishtheeﬃcacyforthe inﬂuenza
vaccination in RA patients treated with Kampo medicines.
Acknowledgment
This paper was supported by a Grant-in-Aid for Scientiﬁc
Research from the Ministry of Health, Labor, and Welfare in
Japan.
References
[1] J. Verwilghen, S. Vertessen, E. A. Stevens, J. Dequeker, and J.
L. Ceuppens, “Depressed T-cell reactivity to recall antigens in
rheumatoid arthritis,” Journal of Clinical Immunology, vol. 10,
no. 2, pp. 90–98, 1990.
[2] J. C. Beckham, D. S. Caldwell, B. L. Peterson et al., “Disease
severityinrheumatoidarthritis:relationshipsofplasmatumor
necrosis factor-alpha, soluble interleukin 2-receptor, soluble
CD4/CD8 ratio, neopterin, and ﬁbrin D-dimer to tradi-
tional severity and functional measures,” Journal of Clinical
Immunology, vol. 12, no. 5, pp. 353–361, 1992.
[3] T. Kogure, T. Itoh, Y. Shimada, T. Shintani, H. Ochiai, and
K. Terasawa, “Detection of serum soluble markers of immune
activationinrheumatoidarthritis,”MediatorsofInﬂammation,
vol. 5, no. 4, pp. 262–265, 1996.
[4] K. Koetz, E. Bryl, K. Spickschen, W. M. O’Fallon, J. J. Goronzy,
and C. M. Weyand, “T cell homeostasis in patients with rheu-
matoid arthritis,” Proceedings of the National Academy of Sci-
ences of the United States of America, vol. 97, no. 16, pp. 9203–
9208, 2000.Evidence-Based Complementary and Alternative Medicine 5
[ 5 ]T .M .G o v a e r t ,C .T .T h i j s ,N .M a s u r e l ,M .J .S p r e n g e r ,G .
J. Dinant, and J. A. Knottnerus, “The eﬃcacy of inﬂuenza
vaccination in elderly individuals: a randomized double-blind
placebo-controlled trial,” Journal of the American Medical
Association, vol. 272, no. 21, pp. 1661–1665, 1994.
[6] M. R. Ehrenstein, J. G. Evans, A. Singh et al., “Compromised
functionofregulatoryTcellsinrheumatoidarthritisandreve-
rsal by anti-TNFα therapy,” Journal of Experimental Medicine,
vol. 200, no. 3, pp. 277–285, 2004.
[7] F. Wolfe, D. M. Mitchell, J. T. Sibley et al., “The mortality of
rheumatoid arthritis,” Arthritis and Rheumatism, vol. 37, no.
4, pp. 481–494, 1994.
[8] Centers for Disease Control and Prevention, “Prevention of
pneumococcal disease: recommendations of the advisory
committeeonimmunizationpractices(ACIP),”Morbidityand
Mortality Weekly Report, vol. 55, pp. 1–42, 2006.
[9] I. Fomin, D. Caspi, V. Levy et al., “Vaccination against
inﬂuenza in rheumatoid arthritis: the eﬀect of disease modify-
ing drugs, including TNFα blockers,” Annals of the Rheumatic
Diseases, vol. 65, no. 2, pp. 191–194, 2006.
[10] A. Chalmers, D. Scheifele, C. Patterson et al., “Immunization
ofpatientswithrheumatoidarthritisagainstinﬂuenza:astudy
of vaccine safety and immunogenicity,” Journal of Rheuma-
tology, vol. 21, no. 7, pp. 1203–1206, 1994.
[11] D. M. Chang, W. Y. Chang, S. Y. Kuo, and M. L. Chang,
“The eﬀects of traditional antirheumatic herbal medicines on
immune response cells,” Journal of Rheumatology, vol. 24, no.
3, pp. 436–441, 1997.
[12] K. Asano, J. Matsuishi, Y. Yu, T. Kasahara, and T. Hisamitsu,
“Suppressive eﬀects of Tripterygium wilfordii Hook f., a tradi-
tionalChinesemedicine,oncollagenarthritisinmice,”Immu-
nopharmacology, vol. 39, no. 2, pp. 117–126, 1998.
[13] S. Kobayashi, H. Kobayashi, H. Matsuno, I. Kimura, and M.
Kimura, “Inhibitory eﬀects of anti-rheumatic drugs contain-
ing magnosalin, a compound from “Shin-I” (Flos magnoliae),
on the proliferation of synovial cells in rheumatoid arthritis
models,” Immunopharmacology, vol. 39, no. 2, pp. 139–147,
1998.
[14] A. Niizawa, T. Kogure, L. X. Hai et al., “Clinical and immuno-
modulatory eﬀects of Fun-boi, an herbal medicine, on collag-
en-induced arthritis in vivo,” Clinical and Experimental Rheu-
matology, vol. 21, no. 1, pp. 57–62, 2003.
[15] L. X. Hai, T. Kogure, A. Niizawa et al., “Suppressive eﬀect of
hochu-ekki-to on collagen induced arthritis in DBA1J mice,”
Journal of Rheumatology, vol. 29, no. 8, pp. 1601–1608, 2002.
[16] T. Kogure, T. Tatsumi, A. Niizawa, H. Fujinaga, Y. Shimada,
and K. Terasawa, “The population of CD40L-expressing cells
was slightly but not signiﬁcant decreased in lymphoid tissues
of collagen induced arthritic mice treated with Hochu-Ekki-
To,” Yakugaku Zasshi, vol. 127, no. 3, pp. 547–550, 2007.
[ 1 7 ]M .L .P r e v o o ,M .A .v a n ’ tH o f ,H .H .K u p e r ,M .A .v a nL e e u -
wen, L. B. van de Putte, and P. L. van Riel, “Modiﬁed disease
activity scores that include twenty-eight-joint counts: develo-
pment and validation in a prospective longitudinal study of
patientswithrheumatoidarthritis,”ArthritisandRheumatism,
vol. 38, no. 1, pp. 44–48, 1995.
[18] A.Holvast,A.Huckriede,J.Wilschutetal.,“Safetyandeﬃcacy
of inﬂuenza vaccination in systemic lupus erythematosus
patients with quiescent disease,” Annals of the Rheumatic
Diseases, vol. 65, no. 7, pp. 913–918, 2006.
[ 1 9 ]J .C .d eJ o n g ,A .M .P a l a c h e ,W .E .B e y e r ,G .F .R i m m e l z w a a n ,
A. C. Boon, and A. D. Osterhaus, “Haemagglutination-inhi-
biting antibody to inﬂuenza virus,” Developments in Biologi-
cals, vol. 115, pp. 63–73, 2003.
[20] I. Fomin, D. Caspi, V. Levy et al., “Vaccination against
inﬂuenza in rheumatoid arthritis: the eﬀect of disease modify-
ing drugs, including TNFα blockers,” Annals of the Rheumatic
Diseases, vol. 65, no. 2, pp. 191–194, 2006.
[21] S. van Assen, A. Holvast, C. A. Benne et al., “Humoral respon-
ses after inﬂuenza vaccination are severely reduced in patients
with rheumatoid arthritis treated with rituximab,” Arthritis
and Rheumatism, vol. 62, no. 1, pp. 75–81, 2010.
[22] T. Nogami, N. Sekiya, T. Mitsuma, and T. Yamaguchi, “A case
of pulmonary Mycobacterium fortuitum infection successful-
ly treated with Kampo treatments,” Kekkaku,v o l .8 1 ,n o .8 ,p p .
525–529, 2006.
[23] N. Mantani, Y. Kasahara, T. Kamata et al., “Eﬀect of Seihai-
to,aKampomedicine,inrelapsingaspirationpneumonia—an
open-label pilot study,” Phytomedicine, vol. 9, no. 3, pp. 195–
201, 2002.
[24] A.Nakajima,E.Inoue,E.Tanakaetal.,“Mortalityandcauseof
death in Japanese patients with rheumatoid arthritis based on
a large observational cohort, IORRA,” Scandinavian Journal of
Rheumatology, vol. 39, no. 5, pp. 360–367, 2010.
[25] M. Bijl, N. Agmon-Levin, J. M. Dayer, E. Israeli, M. Gatto,
and Y. Shoenfeld, “Vaccination of patients with auto-immune
inﬂammatory rheumatic diseases requires careful beneﬁt-risk
assessment,” Autoimmunity Reviews, In press.
[26] F. Conti, S. Rezai, and G. Valesini, “Vaccination and autoim-
mune rheumatic diseases,” Autoimmunity Reviews, vol. 8, no.
2, pp. 124–128, 2008.
[27] L. Stojanovich, “Inﬂuenza vaccination of patients with sys-
temic lupus erythematosus (SLE) and rheumatoid arthritis
(RA),” Clinical and Developmental Immunology, vol. 13, no. 2–
4, pp. 373–375, 2006.
[28] J. Sibilia and J. F. Maillefert, “Vaccination and rheumatoid
arthritis,” Annals of the Rheumatic Diseases,v o l .6 1 ,n o .7 ,p p .
575–576, 2002.
[29] S. Oren, M. Mandelboim, Y. Braun-Moscovici et al., “Vacci-
nation against inﬂuenza in patients with rheumatoid arthritis:
theeﬀect of rituximab on thehumoral response,” Annals ofthe
Rheumatic Diseases, vol. 67, no. 7, pp. 937–941, 2008.
[30] N. Toplak, T. Kveder, A. Trampus-Bakija, V. Subelj, S. Cucnik,
and T. Avcin, “Autoimmune response following annual inﬂue-
nza vaccination in 92 apparently healthy adults,” Autoimmu-
nity Reviews, vol. 8, no. 2, pp. 134–138, 2008.
[31] T. Kogure, H. Sato, D. Kishi, T. Ito, and T. Tatsumi, “Ser-
um levels of anti-cyclic citrullinated peptide antibodies are as-
sociated with a beneﬁcial response to traditional herbal medi-
cine(Kampo)inrheumatoidarthritis,”RheumatologyInterna-
tional, vol. 29, no. 12, pp. 1441–1447, 2009.
[32] C. A. Murphy, C. L. Langrish, Y. Chen et al., “Divergent
pro- and antiinﬂammatory roles for IL-23 and IL-12 in joint
autoimmune inﬂammation,” Journal of Experimental Medi-
cine, vol. 198, no. 12, pp. 1951–1957, 2003.
[33] S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura, “Suppression of
immune induction of collagen-induced arthritis in IL-17-def-
icientmice,”JournalofImmunology,vol.171,no.11,pp.6173–
6177, 2003.
[34] H.Kawamata,H.Ochiai,N.Manlani,andK.Terasawa,“Enha-
nced expression of inducible nitric oxide synthase by Juzen-
Taiho-To in LPS-activated RAW264.7 Cells, a murine macro-
phage cell line,” American Journal of Chinese Medicine, vol. 28,
no. 2, pp. 217–226, 2000.
[35] T. Kogure, A. Niizawa, L. X. Hai et al., “Eﬀect of interleukin 2
on killer cell inhibitory receptors in patients with rheumatoid
arthritis,” Annals of the Rheumatic Diseases,v o l .6 0 ,n o .2 ,p p .
166–169, 2001.6 Evidence-Based Complementary and Alternative Medicine
[36] K. Hayashi, N. Imanishi, Y. Kashiwayama et al., “Inhibitory
eﬀect of cinnamaldehyde, derived from Cinnamomi cortex,
on the growth of inﬂuenza A/PR/8 virus in vitro and in vivo,”
Antiviral Research, vol. 74, no. 1, pp. 1–8, 2007.
[37] N. Mantani, N. Imanishi, H. Kawamata, K. Terasawa, and H.
Ochiai, “Inhibitory eﬀect of (+)-catechin on the growth of in-
ﬂuenza A/PR/8 virus in MDCK cells,” Planta Medica, vol. 67,
no. 3, pp. 240–243, 2001.